<DOC>
	<DOCNO>NCT02905916</DOCNO>
	<brief_summary>The purpose trail evaluate efficacy safety PEG-rhG-CSF primary prophylaxis secondary prophylaxis neutropenia chemotherapy .</brief_summary>
	<brief_title>The Efficacy Safety PEG-rhG-CSF Neutropenia After Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Patients age 18 70 year . 2 . Breast cancer , lymphoma , bone tumor Gynecologic tumor patient . 3 . With multicycle chemotherapy . 4 . With III/IV degree neutropenia last cycle chemotherapy plan use regimen subsequent cycles.FN risk chemotherapy regimens ≥20 % ，or 10 % ≤FN risk＜20 % high risk factor associate FN . 5 . KPS score≥ 70 . 6 . Expected survive 3 month . 7 . No hematologic system disease ANC≥1.5×10E9/L , PKT≥80×10E9/L , Hb≥ 75g/L , WBC≥3×10E9/L , bleed tendency . 8 . Written inform consent acquire . 1 . With infection systemic antibiotic therapy 72h chemotherapy . 2 . With abnormal hematopoietic function . 3 . Received transplantation within 3 month . 4 . Suffered malignant tumor brain metastasis . 5 . TBIL , ALT , AST &gt; 2.5×ULN ; cause liver metastasis , TBIL , ALT , AST &gt; 5×ULN . 6 . Cr &gt; 1.5 ×ULN . 7 . Sensitive product genetically engineer biological product Escherichia coli strain . 8 . Mental nervous system disorder . 9 . Refused accept contraceptive measure . 10 . Other situation investigator consider contraindication study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>